(Q38156198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Clinical applications of attenuated MVA poxvirus strain (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Juan García-Arriaza

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4

Mariano Esteban

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

Beatriz Perdiguero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

30 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1395-1416

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Clinical development of Modified Vaccinia virus Ankara vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Poxvirus vectors as HIV/AIDS vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Prime-boost vectored malaria vaccines: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Viral vector-based therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Poxvirus vector-based HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Smallpox vaccines: Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombinant MVA vaccines: dispelling the myths

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Novel directions in HIV-1 vaccines revealed from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

An avian cell line designed for production of highly attenuated viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A chemically defined production process for highly attenuated poxviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Malaria vaccine design: immunological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A retrospective evaluation of the role of T cells in the development of malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Immunologic basis of vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Effective induction of high-titer antibodies by viral vector vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Immunology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

How can immunology contribute to the control of tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Correlates of protective immunity to Mycobacterium tuberculosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Bettering BCG: a tough task for a TB vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Systems biology in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Systems biology of vaccination for seasonal influenza in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845531

10.1586/14760584.2013.845531

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24168097%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference